ICU Medical, Inc. (ICUI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. ICU Medical, Inc. develops, manufactures, and sells medical products for infusion therapy, vascular access, and vital care. The quarter was defined by the strategic divestiture of a controlling interest in its IV Solutions business and significant debt reduction.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $548.9 million | $1,153.6 million | $596.5 million | $1,163.1 million |
| Gross Profit | $208.1 million | $418.2 million | $207.4 million | $392.7 million |
| Gross Margin | 37.9% | 36.3% | 34.8% | 33.8% |
| Operating Income | $10.6 million | $23.5 million | $7.7 million | $(3.0) million |
| Net Income | $35.3 million | $19.9 million | $(21.4) million | $(60.9) million |
| Diluted EPS | $1.43 | $0.80 | $(0.88) | $(2.51) |
| Cash & Equivalents | $300.0 million | As of June 30, 2025 | ||
| Long-Term Debt | $1,337.7 million | As of June 30, 2025 |
Material Changes vs. Prior Period
- Strategic Divestiture: On May 1, 2025, the Company sold a 60% interest in its IV Solutions business to Otsuka Pharmaceutical Factory America, Inc. (OPF) for preliminary cash proceeds of $209.5 million. This resulted in a $41.8 million gain on sale of business recognized in Q2 2025.
- Debt Reduction: The Company utilized $200.0 million of the divestiture proceeds to prepay Term Loan A. Combined with a $35.0 million prepayment on Term Loan B in Q1, total principal repayments for the six months ended June 30, 2025, were $247.8 million.
- Revenue Mix: Total revenue decreased 8.0% in Q2 2025 compared to Q2 2024, primarily driven by the exit from the IV Solutions business (Vital Care segment). However, Consumables revenue grew 4.3% and Infusion Systems revenue grew 2.4%.
- Profitability: The Company returned to profitability, reporting Net Income of $35.3 million in Q2 2025 compared to a Net Loss of $21.4 million in Q2 2024. Gross margins expanded due to the divestiture of the lower-margin IV Solutions business and operational efficiencies.
Guidance, Outlook, and Risks
- Capital Expenditures: Estimated 2025 capital expenditures are now projected at $75 million to $95 million, reduced from the prior $90 million to $110 million range due to the IV Solutions disposal.
- Regulatory Contingencies:
- 2025 FDA Warning Letter: Received in April 2025 regarding modifications to MedFusion and CADD Solis VIP pumps. The Company submitted 510(k) applications in July 2025. No loss contingency has been recorded as the outcome is not yet probable or estimable.
- 2021 FDA Warning Letter: Related to Smiths Medical's Oakdale facility. As of June 30, 2025, approximately $25.8 million remains accrued for field service corrective actions.
- Tariff Risks: The Company incurred $12.3 million in tariffs in Q2 2025. Recent U.S. announcements regarding reciprocal tariffs (e.g., 15% on Costa Rica) pose a risk to future margins, particularly for products manufactured in Costa Rica and Mexico.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was enacted on July 4, 2025. The Company is assessing its impact, but it is not reflected in Q2 2025 results.
Investor Verification Checklist
- Divestiture Accounting: Verify the final purchase price adjustments and the valuation of the retained 40% equity interest in the Otsuka ICU Medical LLC joint venture.
- Regulatory Resolution: Monitor the FDA's response to the July 2025 510(k) submissions regarding the MedFusion and CADD Solis VIP pumps to assess potential future costs or sales restrictions.
- Tariff Exposure: Assess the impact of the new 15% reciprocal tariff on Costa Rican imports and the stability of USMCA exemptions for Mexican manufacturing.
- Debt Covenants: Confirm continued compliance with the Senior Secured Leverage Ratio (max 4.00:1.00) and Interest Coverage Ratio (min 3.00:1.00) following the debt prepayments.
- Joint Venture Performance: Track the equity earnings from the 40% retained interest in the IV Solutions joint venture as a new revenue stream.